Document is current
Any future updates will be listed below
-
Authors
van Straalen, Joeri W. https://orcid.org/0000-0002-8766-6694
de Roock, Sytze
Giancane, Gabriella
Consolaro, Alessandro
Rygg, Marite
Nordal, Ellen B.
Rubio-Pérez, Nadina
Jelusic, Marija
De Inocencio, Jaime
Vojinovic, Jelena
Wulffraat, Nico M.
Bruijning-Verhagen, Patricia C. J.
Ruperto, Nicolino
Swart, Joost F.
,
Pallotti, Chiara
Scala, Silvia
Angioloni, Simona
Villa, Luca
-
Funding
Funding for this research was provided by:
European Union (260353)
IRCCS Istituto Giannina Gaslini
ZonMW (PharmachildNL 80-83600-98-21012)
- License Information
-
More Information
Article History
Received: 31 August 2022
Accepted: 29 October 2022
First Online: 14 November 2022
Declarations
:
: Pharmachild and all participating centers obtained approval from their respective ethics committees and were conducted in accordance with the Declaration of Helsinki. All patients provided written informed consent/assent based on existing national regulations.
: Not applicable.
: AC reports speaking fees from AbbVie and Pfizer and a research grant from Pfizer. NR has received honoraria for consultancies or speaker bureaus from the following pharmaceutical companies in the past 3 years: 2 Bridge, Amgen, AstraZeneca, Aurinia, Bayer, Brystol Myers and Squibb, Celgene, inMed, Cambridge Healthcare Research, Domain Therapeutic, EMD Serono, Glaxo Smith Kline, Idorsia, Janssen, Eli Lilly, Novartis, Pfizer, Sobi, UCB. All other authors declare no conflict of interest for this manuscript.
